ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

British Journal of Haematology

Volumn 151, Issue 4, 2010, Pages 365-375

  Gelsi Boyer, Véronique ^a,b   Trouplin, Virginie ^a   Roquain, Julien ^a   Adélaïde, José ^a   Carbuccia, Nadine ^a   Esterni, Benjamin ^a   Finetti, Pascal ^a   Murati, Anne ^a,b   Arnoulet, Christine ^b   Zerazhi, Hacène ^c   Fezoui, Hacène ^d   Tadrist, Zoulika ^e   Nezri, Meyer ^f   Chaffanet, Max ^a   Mozziconacci, Marie Joëlle ^a   Vey, Norbert ^a   Birnbaum, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE HOSPITALIER D AVIGNON   (France)

^d Centre Hospitalier Intercommunal Toulon La Seyne sur Mer   (France)

^e Centre Hospitalier de Salon de Provence   (France)

^f Centre Hospitalier Genéral   (France)

Author keywords

Array CGH; ASXL1; Chronic myelomonocytic leukaemia; Gene mutation; Mutations; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; ASXL1 GENE; CANCER SURVIVAL; CBL GENE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLT 3 GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; JAK2 GENE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NPM1 GENE; NRAS GENE; PRIORITY JOURNAL; PROGNOSIS; PTPN11 GENE; RUNX1 GENE; TET2 GENE; WT1 GENE;

ADULT; AGED; AGED, 80 AND OVER; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; REPRESSOR PROTEINS; SURVIVAL ANALYSIS;

EID: 77958591628     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08381.x     Document Type: Article

References (31)

1. Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., Schoenmakers, E., Viens, P., Jacquemier, J., Birnbaum, D., Bertucci, F. & Chaffanet, M. (2007) Integrated profiling of basal and luminal breast cancers. Cancer Research, 67, 11565-11575.
2. Adélaïde, J., Rocquain, J., Gelsi-Boyer, V., Carbucci, N., Birnbaum, D.J., Mozziconacci, M.J., Vey, N., Birnbaum, D. & Chaffanet, M. (2010) Gain of CBL-interacting protein: a possible alternative to CBL mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia, 24, 1539-1541.
3. Barrett, M.T., Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer, P.S., Yakhini, Z., Bruhn, L. & Laderman, S. (2004) Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proceedings of the National Academy of Sciences of the United States of America, 101, 17765-17770.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
5. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H., Sultan, C. & Cox, C. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. British Journal of Haematology, 84, 746-754.
6. Bernard, F., Gelsi-Boyer, V., Murati, A., Giraudier, S., Trouplin, V., Adélaïde, J., Rey, J., Olschwang, S., Vainchenker, W., Chaffanet, M., Vey, N., Mozziconacci, M.J. & Birnbaum, D. (2008) Alterations of NFIA in chronic malignant myeloid diseases. Leukemia, 23, 583-535.
7. Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. (2010a) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 24, 1062-1065.
8. Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., Kusec, R., Pellagatti, A., Wang, L., Clark, R.E. & Wainscoat, J.S. (2010b) High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia, 24, 1139-1145.
9. Carbuccia, N., Murati, A., Trouplin, V., Brecqueville, M., Adélaïde, J., Rey, J., Vainchenker, W., Bernard, O.A., Chaffanet, M., Vey, N., Birnbaum, D. & Mozziconacci, M.J. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, 23, 2183-2186.
10. Carbuccia, N., Trouplin, V., Gelsi-Boyer, V., Murati, A., Rocquain, J., Adélaïde, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., Birnbaum, D. & Mozziconacci, M.J. (2010) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 24, 469-473.
11. Etienne, A., Carbuccia, N., Adélaïde, J., Bekhouche, I., Remy, V., Sohn, C., Sainty, D., Gastaut, J.A., Olschwang, S., Birnbaum, D., Mozziconacci, M.J. & Chaffanet, M. (2007) Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genetics and Cytogenetics, 176, 80-88.
12. Gelsi-Boyer, V., Cervera, N., Bertucci, F., Trouplin, V., Remy, V., Olschwang, S., Chaffanet, M., Vey, N., Mozziconacci, M.J. & Birnbaum, D. (2007) Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. Leukemia, 21, 2359-2362.
13. Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., Olschwang, S., Vey, N., Mozziconacci, M.J., Birnbaum, D. & Chaffanet, M. (2008) Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer, 8, 299-315.
14. Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 145, 788-800.
15. Germing, U., Gattermann, N., Minning, H., Heyll, A. & Aul, C. (1998) Problems in the classification of CMML - dysplastic versus proliferative type. Leukemia Research, 22, 871-878.
16. Gonzalez-Medina, I., Bueno, J., Torrequebrada, A., Lopez, A., Vallespi, T. & Massague, I. (2002) Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leukemia Research, 26, 821-824.
17. Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., Stamatoulas, A., Dreyfus, F., Ifrah, N., De Botton, S., Vainchenker, W., Bernard, O.A., Birnbaum, D., Fontenay, M. & Solary, E. (2009a) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676-1681.
18. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguie, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, M., Fenaux, P., Mansat-De Mas, V., Delabesse, E., Guardiola, P., Lacombe, C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, D. & Fontenay, M. (2009b) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-3291.
19. Kuo, M.C., Liang, D.C., Huang, C.F., Shih, Y.S., Wu, J.H., Lin, T.L. & Shih, L.Y. (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia, 23, 1426-1431.
20. Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R.L., Kojima, S., List, A.F., Sekeres, M.A., McDevitt, M.A. & Maciejewski, J.P. (2009) Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology, 27, 6109-6116.
21. Murati, A., Adélaïde, J., Popovici, C., Mozziconacci, M.J., Arnoulet, C., Lafage-Pochitaloff, M., Sainty, D., Birnbaum, D. & Chaffanet, M. (2003) A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. International Journal of Molecular Medicine, 12, 423-428.
22. Nosslinger, T., Reisner, R., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E. & Pfeilstöcker, M. (2001) Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. Leukemia Research, 25, 741-747.
23. Padua, R.A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F. & Jacobs, A. (1988) RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia, 2, 503-510.
24. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 12, 887-892.
25. Ricci, C., Fermo, E., Corti, S., Molteni, M., Faricciotti, A., Cortelezzi, A., Lambertenghi Deliliers, G., Beran, M. & Onida, F. (2010) RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clinical Cancer Research, 16, 2246-2256.
26. Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V. & Mozziconacci, M.J. (2010a) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 10, 401.
27. Rocquain, J., Gelsi-Boyer, V., Adélaïde, J., Murati, A., Carbuccia, N., Vey, N., Mozziconacci, M.J., Birnbaum, D. & Chaffanet, M. (2010b) Alteration of cohesin genes in myeloid diseases. American Journal of Hematology (in press).
28. Sugimoto, Y., Muramatsu, H., Makishima, H., Prince, C., Jankowska, A.M., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., Takahashi, Y., Kato, K., Manabe, A., Kojima, S. & Maciejewski, J.P. (2010) Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. British Journal of Haematology, 150, 83-87.
29. Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-1138.
30. Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The world health classification (WHO) of myeloid neoplasms. Blood, 100, 2292-2302.
31. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.